Nakatsura; Tetsuya

Patent Applications and Registrations

Patent applications and USPTO patent grants for Nakatsura; Tetsuya.The latest application filed is for "novel t-cell receptor".

Company Profile

7.10.16

Nakatsura; Tetsuya - Chiba JP
- Chiba JP
NAKATSURA; Tetsuya - Kashiwa-shi JP
Nakatsura; Tetsuya - Kashiwa JP
Nakatsura; Tetsuya - Kumamoto JP
Nakatsura; Tetsuya - Kikuchi-gun JP

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Anti-GPC3 antibody Grant 10,781,249 - Tamada , et al. Sept	2020-09-22
Anti-GPC3 antibody Grant 10730935 -	2020-08-04
Novel T-cell Receptor App 20200010804 - Nakatsura; Tetsuya ; et al.	2020-01-09
Anti-gpc3 Antibody App 20190367634 - TAMADA; KOJI ; et al.	2019-12-05
Anti-gpc3 Antibody App 20190359698 - TAMADA; Koji ; et al.	2019-11-28
Undifferentiated Stem Cell Removal Agent And Method For Removing Undifferentiated Stem Cells App 20190350979 - FUKUDA; Keiichi ; et al.	2019-11-21
Method, Apparatus, Computer Program Product And Kit For Assisting Recurrence Risk Prediction For Hepatocellular Carcinoma Patients App 20190066846 - NAKATSURA; Tetsuya ; et al.	2019-02-28
Antigen Peptide Derived From the Sequence of Epidermal Growth Factor Receptor Having T790M Point Mutation App 20170049870 - Sasada; Tetsuro ; et al.	2017-02-23
Antigen peptide derived from the sequence of epidermal growth factor receptor having T790M point mutation Grant 9,505,824 - Sasada , et al. November 29, 2	2016-11-29
Kit for diagnosing malignant melanoma Grant 9,465,030 - Nakatsura , et al. October 11, 2	2016-10-11
Cancer antigen and use thereof Grant 9,404,925 - Nakatsura , et al. August 2, 2	2016-08-02
Antigen Peptide Originated From T790M Point-Mutated Sequence of Epidermal Growth Factor Receptor App 20150218248 - Sasada; Tetsuro ; et al.	2015-08-06
Kit For Diagnosing Malignant Melanoma App 20150198598 - Nakatsura; Tetsuya ; et al.	2015-07-16
Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the same Grant 8,535,942 - Nishimura , et al. September 17, 2	2013-09-17
Cell Evaluation Method App 20130045500 - Tanaka; Satoru ; et al.	2013-02-21
Glypican-3 (gpc3)-derived Tumor Rejection Antigenic Peptides Useful For Hla-a2-positive Patients And Pharmaceutical Comprising The Same App 20120040452 - NISHIMURA; Yasuharu ; et al.	2012-02-16
Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the same Grant 8,053,556 - Nishimura , et al. November 8, 2	2011-11-08
Diagnostic kit for malignant melanoma Grant 8,017,345 - Nishimura , et al. September 13, 2	2011-09-13
Diagnostic agent for malignant melanoma Grant 7,803,533 - Nishimura , et al. September 28, 2	2010-09-28
Glypican-3 (gpc3)-derived Tumor Rejection Antigenic Peptides Useful For Hla-a2-positive Patients And Pharmaceutical Comprising The Same App 20090239806 - Nishimura; Yasuharu ; et al.	2009-09-24
Novel Diagnostic Kit For Malignant Melanoma App 20090111095 - Nishimura; Yasuharu ; et al.	2009-04-30
Cancer antigen and use thereof App 20090074800 - Nakatsura; Tetsuya ; et al.	2009-03-19
Diagnositic Agent for Malignant Melanoma App 20080044818 - Nishimura; Yasuharu ; et al.	2008-02-21
Cancer antigens and utilization thereof App 20060251666 - Nakatsura; Tetsuya ; et al.	2006-11-09

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.